P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Paul G. Richardson,Joseph R. Mikhael,Saad Z. Usmani,Noopur Raje,William I. Bensinger,Dheepak Kanagavel,Lei Gao,Samira Ziti-Ljajic,Kenneth C. Anderson +8 more
TL;DR: Based on initial safety, efficacy, and PK data, ISA 10 mg/kg was chosen as the recommended dose for the expansion cohort of a Phase Ib study of ISA plus Pom and dex in pts with RRMM.
Journal ArticleDOI
MM-096: Isatuximab Short-Duration Fixed-Volume Infusion Combination Therapy for Relapsed/Refractory Multiple Myeloma: Final Results of a Phase 1b Feasibility/Safety Study
Saad Z. Usmani,Chatchada Karanes,William I. Bensinger,Anita D'Souza,Noopur Raje,Sascha A. Tuchman,Douglas W. Sborov,Dheepak Kanagavel,Rao Saleem,Franck Dubin,Frank Campana,Paul G. Richardson +11 more
TL;DR: Efficacy and safety findings were consistent with Part A of this study and the pivotal Phase 3 ICARIA study, and confirm the safety, efficacy, and feasibility of Isa administered by a fixed infusion volume.
Journal ArticleDOI
Evolving Strategies in the Initial Treatment of Multiple Myeloma
Cara A. Rosenbaum,Jagoda Jasielec,Jacob P. Laubach,Claudia Paba Prada,Paul G. Richardson,Andrzej Jakubowiak +5 more
TL;DR: With an improvement in the tolerability of newer regimens and the deferral of ASCT in transplant candidates, the debate has emerged whether the two-pathway approach to the treatment of newly diagnosed myeloma should be re-evaluated.
Journal ArticleDOI
The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome
Tarek H. Mouhieddine,Jihye Park,Robert A. Redd,Christopher J. Gibson,Salomon Manier,Amin Nassar,Marzia Capelletti,Daisy Huynh,Mark Bustoros,Romanos Sklavenitis-Pistofidis,Kalvis Hornburg,Henry Dumke,Muhieddine M. Itani,Cody J. Boehner,Chia Jen Liu,Chia Jen Liu,Saud H. AlDubayan,Brendan Reardon,Eliezer M. Van Allen,Daniel Auclair,Robert L. Schlossman,Nikhil C. Munshi,Kenneth C. Anderson,David P. Steensma,Jacob P. Laubach,Paul G. Richardson,Jerome Ritz,Benjamin L. Ebert,Robert J. Soiffer,Donna Neuberg,Irene M. Ghobrial +30 more
TL;DR: The role of CHIP on survival of MM patients, specifically those receiving immunomodulator (IMiD) maintenance (Lenalidomide or Thalidomides) post autologous stem cell transplant (ASCT) is sought, and the most commonly detected mutated genes were DNMT3A, TET2, TP53, ASXL1 and PPM1D.
Journal Article
How to be moderately halophilic with a broad salt tolerance: Cluesfrom the genome of chromohalobacter salexigens
TL;DR: There is a major difference between the proteins of the moderate halophile C. salexigens and non-halophilic bacteria in their periplasmic proteins, exemplified by the substrate binding proteins of transport systems, suggesting the highly acidic nature of these proteins may enable them to function at high salt concentrations.